Equity Overview
Price & Market Data
Price: $8.83
Daily Change: +$0.605 / 6.86%
Daily Range: $8.83 - $8.83
Market Cap: $1,116,352,090
Daily Volume: 2,000
Performance Metrics
1 Week: 7.36%
1 Month: 3.52%
3 Months: -31.62%
6 Months: -33.08%
1 Year: 20.26%
YTD: -31.64%
Details
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.